A Phase 3, Randomized, Double-Blind Comparative Study of the Efficacy and Safety of Topical Recombinant Human Thrombin and Bovine Thrombin in Surgical Hemostasis

止血 医学 凝血酶 血栓弹性成像 凝结 不利影响 随机对照试验 外科 内科学 血小板
作者
William C. Chapman,Neil Singla,Yuri Genyk,James W. McNeil,Kenneth L. Renkens,Thomas C. Reynolds,Aileen Murphy,Fred A. Weaver
出处
期刊:Journal of The American College of Surgeons [Elsevier]
卷期号:205 (2): 256-265 被引量:170
标识
DOI:10.1016/j.jamcollsurg.2007.03.020
摘要

BACKGROUND: Plasma-derived bovine thrombin is used as a topical agent to improve surgical hemostasis, but development of antibodies to bovine hemostatic proteins has been associated with increased bleeding and thrombotic complications. Recombinant human thrombin could reduce the risk of these complications. STUDY DESIGN: The objective of this randomized, double-blind, comparative trial was to compare the efficacy, safety, and antigenicity of recombinant human thrombin (rhThrombin) and bovine thrombin as adjuncts to hemostasis in liver resection, spine, peripheral arterial bypass, and dialysis access surgery. Blinded study drug was applied topically to bleeding sites with an absorbable gelatin sponge. The primary efficacy end point was time to hemostasis, summarized as the incidence of hemostasis within 10 minutes. Safety analyses were conducted for 1 month after operation, and the development of antibodies to rhThrombin or to the bovine product was evaluated. RESULTS: Four hundred one patients completed this trial. Hemostasis was achieved at the time-to-hemostasis evaluation site within 10 minutes in 95% of patients in each treatment group. Overall complications, including operative mortality, adverse events, and laboratory abnormalities, were similar between groups. Forty-three (21.5%) patients receiving bovine thrombin developed antibodies to the product; three patients (1.5%; p < 0.0001) in the rhThrombin group developed antibodies to rhThrombin. None of the three patients who developed antirhThrombin antibodies had abnormal coagulation laboratory results or bleeding, thromboembolic, or hypersensitivity events. CONCLUSIONS: Results of this trial suggest that rhThrombin has comparable efficacy, a similar safety profile, and is considerably less immunogenic than bovine thrombin when used for surgical hemostasis. Abbreviations and Acronyms: bThrombin: bovine thrombin; INR: international normalized ratio; PAB: peripheral arterial bypass; PT: prothrombin time; rhThrombin: recombinant human thrombin; TTH: time to hemostasis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
XIN完成签到,获得积分10
1秒前
天天快乐应助LZJ采纳,获得10
1秒前
1秒前
1秒前
1134695021完成签到,获得积分10
2秒前
xxx完成签到,获得积分10
2秒前
搜集达人应助缘来如风采纳,获得10
3秒前
德德发布了新的文献求助10
3秒前
3秒前
4秒前
5秒前
小马甲应助Du采纳,获得10
5秒前
wenbinvan完成签到,获得积分0
7秒前
7秒前
顺利三毒发布了新的文献求助10
8秒前
大橙子完成签到,获得积分10
9秒前
9秒前
隐形曼青应助Lion采纳,获得10
9秒前
9秒前
小白完成签到,获得积分10
9秒前
11秒前
深年完成签到,获得积分10
13秒前
哈哈哈哈哈哈完成签到,获得积分20
13秒前
行风浅浅完成签到,获得积分10
13秒前
缘来如风发布了新的文献求助10
14秒前
二月姹紫嫣红完成签到 ,获得积分10
14秒前
AXLL完成签到 ,获得积分10
15秒前
jiang发布了新的文献求助10
15秒前
港港完成签到 ,获得积分10
16秒前
张琼敏发布了新的文献求助10
16秒前
苦行僧完成签到,获得积分10
16秒前
SciGPT应助cctoday采纳,获得10
17秒前
温柔诗柳发布了新的文献求助10
17秒前
17秒前
18秒前
搜集达人应助酷炫葵阴采纳,获得10
18秒前
ding应助jessietang采纳,获得10
19秒前
丘比特应助孤独的电话采纳,获得30
20秒前
情怀应助TigerOvO采纳,获得20
20秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3154081
求助须知:如何正确求助?哪些是违规求助? 2804993
关于积分的说明 7862902
捐赠科研通 2463094
什么是DOI,文献DOI怎么找? 1311144
科研通“疑难数据库(出版商)”最低求助积分说明 629460
版权声明 601821